A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents
This is the first study of the safety of increasing dose levels of AEB1102 in patients with
Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will
also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid
levels and the antitumour effects of AEB1102.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society